Course of C-reactive protein during continuous peritoneal dialysis-associated peritonitis

Nephrology

Volumn 10, Issue 5, 2005, Pages 442-445

  Troidle, Laura ^a   Kliger, Alan ^a   Gorban Brennan, Nancy ^a   Finkelstein, Fredric ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

C reactive protein; Continuous peritoneal dialysis therapy; Gram negative; Gram positive; Mortality; Outcome; Peritonitis

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MORBIDITY; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONITIS; RISK FACTORS;

EID: 28444482029     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00442.x     Document Type: Article

References (24)

1. Burkart J, Schreiber M, Tabor T, Korbet S, Stallard R, PD Collaborative Group. Prospective, multicenter evaluation of patient transfer from PD to HD in 1995 (Abstract). Perit. Dial. Int. 1996; 16 (Suppl. 2): S66.
2. Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J. Am. Soc. Nephrol. 1996; 7: 2176-82.
3. Piraino B. A review of Staphylococcus aureus exit-site and tunnel infections in peritoneal dialysis patients. Am. J. Kidney Dis. 1990; 16: 89-95.
4. Kiernan L, Kliger A, Gorban-Brennan N, Juergensen P, Finkelstein F. Comparison of continuous ambulatory peritoneal dialysis-related infections with different 'Y-tubing' exchange systems. J. Am. Soc. Nephrol. 1995; 5: 1835-8.
5. Troidle L, Watnick S, Wuerth DB, Gorban-Brennan N, Kliger AS, Finkelstein FO. Depression and its association with peritonitis in long-term peritoneal dialysis patients. Am. J. Kidney Dis. 2003; 42: 350-54.
6. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 2002; 347: 1557-65.
7. Rost NS, Wolf PA, Kase CS et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham study. Stroke 2001; 32: 2575-9.
8. Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am. J. Cardiol. 2004; 93: 1238-42.
9. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int. 2002; 61 (Suppl. 80): S99-S102.
10. Syrjala H, Linnanvuo-Laitinen M, Huttunen K. Peritoneal effluent leukocytes and serum C-reactive protein during peritoneal dialysis-associated peritonitis. Peru. Dial. Int. 1990; 10: 109-10.
11. Hind CRK, Thomson SP, Winearls CG, Pepys MB. Serum C-reactive protein concentration in the management of infection in patients treated by continuous ambulatory dialysis. J. Clin. Pathol. 1985; 38: 458-63.
12. Troidle L, Gorban-Brennan N, Kliger A, Finkelstein FO. Differing outcomes of gram-positive and gram-negative peritonitis. Am. J. Kidney Dis. 1998; 32: 623-8.
13. Labarrere CA, Lee JB, Nelson DR, Al-Hassani M, Miller SJ, Pitts DE. C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: A prospective study. Lancet 2002; 360: 1462-7.
14. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int. 2002; 62: 1417-22.
15. Amann K, Gross M, Ritz E. Pathophysiology underlying accelerated atherogenesis in renal disease: Closing in on the target. J. Am. Soc. Nephrol. 2004; 15: 1664-6.
16. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
17. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-4.
18. Verma S, Li SH, Badiwala MV et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 1890-96.
19. Verma S, Wang CH, Li SH et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-19.
20. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: Data from the third national health and nutrition examination survey. Arch. Intern. Med. 2004; 164: 1010-14.
21. Finkelstein E, Jekel J, Troidle L, Gorban-Brennan N, Finkelstein FO, Bia FJ. Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. Am. J. Kidney Dis. 2002; 39: 1278-86.
22. Troidle L, Gorban-Brennan N, Finkelstein F. Peritonitis with Staphylococcus aureus. J. Am. Soc. Nephrol. 2002; 13: 384A.
23. Khaled GH, Finkelstein FO, Carey HB, Wardlaw SC, Kliger AS, Edberg SC. Method for studying development of colonization and infection of dialysis catheters. Adv. Perit. Dial. 2001; 17: 163-71.
24. Troidle L, Gorban-Brennan N, Khaled GH, Edberg SC, Finkelstein FO. Biofilm and its clinical significance. Perit. Dial. Int. 2002; 22 (Suppl. 1): S44.